Navigation Links
Medivation Announces Presentation of Full Top-Line Data From,Dimebon Six-Month Trial at Major International Alzheimer's Disease,Conference

ut Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. You are also cautioned that none of the Company's product candidates has been approved for sale, that significant additional animal and human testing is required in order to seek marketing approval for any of its product candidates, and that Medivation cannot assure you that marketing approval can be obtained for any of its product candidates. Medivation's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-KSB for the year ended December 31, 2006, include more information about factors that could affect the Company's financial and operating results.

CONTACT: Patrick Machado, Chief Financial Officer, Medivation, Inc.,+1-415-543-3470, ext. 201; or Jani Bergan of WeissComm Partners,+1-415-946-1064, for Medivation; or Lori Williams of Baylor College ofMedicine, Office of Public Affairs
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/14/2009)... Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) today ... Allowance from the United States Patent and Trademark ... no. 11/060,641, which covers the composition and use ... the lead Transcept product candidate. Once issued, ... 2025. ,, "This is the second USPTO Notice ...
(Date:12/14/2009)... -- In response to an FDA notice ... the Agency recommended that healthcare facilities discontinue use ... system, hospitals throughout the U.S. are faced with ... product. According to the FDA, STERIS made changes ... affect the safety or the effectiveness of the ...
(Date:12/14/2009)... Dec. 14 The board of directors of ... today declared a dividend for the first quarter of ... ,, The dividend is payable March 10, ... business on ,, February 12, 2010. ,, Lilly, ... of pharmaceutical products by applying the latest research from ...
Breaking Medicine Technology:Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 2Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 3Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 4ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Pharma and Biotech Leaders to Converge in Shanghai 14765 1Pharma and Biotech Leaders to Converge in Shanghai 14765 2CEL SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 14763 1CEL SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 14763 2CEL SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 14763 3AMD LASERS Names Dr James Jesse as Medical Director 6091 1AMD LASERS Names Dr James Jesse as Medical Director 6091 2
... Assess the Safety and Efficacy of ORMD 0801, Oral Insulin Capsule, ... ... (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer,of oral delivery systems, announced today ... capsule, on Type 1 diabetics at the,Hadassah University Medical Center in Jerusalem, ...
... SAN MATEO, Calif., Sept. 24 Anthera ... the U.S. Food and Drug,Administration (FDA) on ... in acute,coronary syndrome (ACS) under the FDA,s ... the company received Scientific Advice from,the European ...
Other Medicine Technology:Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics 2Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 2Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 3
(Date:12/14/2009)... Americold Realty Trust ("Americold") announced today that it has ... U.S. Securities and Exchange Commission (the "SEC") relating to ... The number of shares to be offered and the ... determined. The common shares to be sold in this ... ,, The joint book-running managers of the offering will ...
(Date:12/14/2009)... -- Aflac Incorporated announced today that it has ... notes with a coupon of 6.9%. The notes ... to yield 6.984%. The company anticipates using the ... general corporate purposes. ,, Commenting on the pricing ... Chief Financial Officer Kriss Cloninger III commented: "This ...
(Date:12/14/2009)... -- Tough Enough To Wear Pink(TM) (TETWP), the ... its fifth anniversary at the signature Tough Enough ... Finals Rodeo (Wrangler NFR) in Las Vegas. While ... cowboys, the support of the western industry and ... sported pink shirts, hats, bracelets and more. ...
(Date:12/14/2009)... 13 years under government controlled health care, before moving to the ... engagements and in his new book, Health Reform: The End of ... a system and its threat to real health care! , ... ... a diagnostic radiologist from Minnesota, warns Americans not to sell out ...
(Date:12/14/2009)... Dec. 14 Skilled nursing facilities (SNFs) in ... in order to deal with a 92 percent increase ... from $6.25 to $12.01 per bed per day, scheduled ... average facility will pay an additional $17,520 to the ... total tax of $438,365 yearly. ,, Nearly 96 percent ...
Breaking Medicine News(10 mins):Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3
... ArlenGroup, the leading provider,of employee benefit consulting and ... law firms, announces the expansion of its West ... Rees LLP has entered the,Consortium beginning January 1, ... LLP, and Wilson Sonsini Goodrich & Rosati PC ...
... from the Center for Bioinformatics at Peking University ... atlas underlying drug addiction and identified five molecular ... This novel paper appears in PLoS Computational Biology ... a serious worldwide problem with strong genetic and ...
... workers or those with narcolepsy, scientists say , FRIDAY, Jan. ... orexin-A may be key to undoing the negative mental effects ... Orexin-A is a peptide (a kind of protein) made in ... the Wake Forest University School of Medicine in Winston-Salem, N.C. ...
... key articles of interest to caregivers and those who suffer ... of leukemia, and how different societies have looked at the ... describe new research based on identifying the many variations ... sub-types more precisely , show ...
... Highest Honor for Organizational Performance Excellence, ANN ... (MQC) announces Oakwood Healthcare, Inc. as a 2007 ... Award is the highest honor for,organizational performance excellence ... review by a team of examiners who perform ...
... The Michael J. Fox,Foundation has committed up to ... therapeutic to treat Parkinson,s disease by reducing expression,of ... by Matt Farrer,PhD, of Mayo Clinic Jacksonville (Florida) ... and Clinical Center will work,to optimize a small ...
Other Medicine News:Health News:Gordon & Rees LLP Joins ArlenGroup-CIGNA Health Care Purchasing Consortium 2Health News:Gordon & Rees LLP Joins ArlenGroup-CIGNA Health Care Purchasing Consortium 3Health News:Protein Nasal Spray Revives Sleep-Deprived Monkeys 2Health News:Michigan Quality Council (MQC) Names Oakwood Healthcare Inc. 2007 State Quality Award Recipient 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 3
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
...
Medicine Products: